Antisense IRAK-2 oligodeoxynucleotide inhibits interleukin-1-induced nuclear factor-kappa B activation in vitro
Abstract
"AIM:
To study the inhibitory effects of antisense interleukin-1 receptor associated kinase-2 (IRAK-2) oligodeoxynucleotide (ODN) on interleukin-1 (IL-1)-stimulated nuclear factor-kappa B (NF-kappa B) activation.
METHODS:
Antisense IRAK-2 ODN was delivered by lipofectin encapsulation into human embryonic kidney 293 cells (HEK 293 cells). The levels of NF-kappa B were assayed by sandwich ELISA.
RESULTS:
(1) Treatment of HEK 293 cells with IL-1 enhanced NF-kappa B level in nuclei by 518.5% +/- 2.1%. (2) Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation in a concentration (1-8 micrograms)- and time (5-24 h)-dependent manner. A maximum inhibition was 70.7% +/- 1.0% from Acontrol 0.834 +/- 0.014 to 0.244 +/- 0.008 after treatment with antisense IRAK-2 ODN 4 micrograms for 8 h.
CONCLUSION:
Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation."
Keywords:
To study the inhibitory effects of antisense interleukin-1 receptor associated kinase-2 (IRAK-2) oligodeoxynucleotide (ODN) on interleukin-1 (IL-1)-stimulated nuclear factor-kappa B (NF-kappa B) activation.
METHODS:
Antisense IRAK-2 ODN was delivered by lipofectin encapsulation into human embryonic kidney 293 cells (HEK 293 cells). The levels of NF-kappa B were assayed by sandwich ELISA.
RESULTS:
(1) Treatment of HEK 293 cells with IL-1 enhanced NF-kappa B level in nuclei by 518.5% +/- 2.1%. (2) Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation in a concentration (1-8 micrograms)- and time (5-24 h)-dependent manner. A maximum inhibition was 70.7% +/- 1.0% from Acontrol 0.834 +/- 0.014 to 0.244 +/- 0.008 after treatment with antisense IRAK-2 ODN 4 micrograms for 8 h.
CONCLUSION:
Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation."